Autolus Therapeutics Wins 2026 Prix Galien UK Award for Best Biotechnology Product
Key Insights
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product from the Galien Foundation.
The award was selected by a UK Awards Committee comprising 12 leading experts in UK healthcare.
Dr. Martin Pule, Founder and CSO of Autolus, highlighted the company's collaboration with University College London in translating pioneering research into new treatments.
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies, has been honored with the 2026 Prix Galien UK Award for Best Biotechnology Product, the company announced on June 12, 2026. The prestigious award, presented by the Galien Foundation, was selected by a UK Awards Committee composed of 12 experts who are leaders in UK healthcare.
"We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with University College London, to translate pioneering scientific research into new treatment options for patients in need. As a clinician, it is tremendously rewarding to see this vision become a reality. This award reflects the dedication of our teams, whose work is driven every day by a shared commitment to patients," said Dr. Martin Pule, Founder and Chief Scientific Officer of Autolus, Clinical Senior Lecturer in the Department of Haematology at the UCL Cancer Institute, and Honorary Consultant in Haematology at University College London Hospital.
The Prix Galien: A Benchmark of Excellence
The Prix Galien, established in Paris in 1970 by Roland Mehl in honor of Galien — the father of medical science and modern pharmacology — is widely regarded as the equivalent of the Nobel Prize in biopharmaceutical research. The Galien Foundation's mission is to foster, recognize, and reward excellence in scientific innovation with the goal of improving human health. Its vision is to serve as a catalyst for the development of the next generation of treatments and technologies that will transform medical practice and save lives.
Autolus and Its Next-Generation T Cell Platform
Autolus Therapeutics is a commercial-stage biopharmaceutical company developing, manufacturing, and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. The company employs a broad suite of proprietary and modular T cell programming technologies to engineer precisely targeted and controlled T cell therapies. These therapies are designed to better recognize target cells, break down their defense mechanisms, and eliminate them.
The company has a marketed therapy and a pipeline of product candidates in development spanning hematological malignancies, solid tumors, and autoimmune diseases. Autolus was founded in collaboration with University College London, underscoring its deep academic roots and commitment to translating pioneering scientific research into clinical applications.